A novel agent targeting APRIL: A new hope for elderly patients of IgA nephropathy
Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and neutralizes the activity of APRIL. It should usher in a new era in the treatment of IgAN, especially in elderly patients.
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2025-02-01
|
| Col·lecció: | Aging Medicine |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/agm2.12370 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|